FDA's inter-agency drug shortage task force wants comments on whether new shortage prevention and mitigation policies should include closer examination of mergers and acquisitions that could create drug shortages.
US regulators may consider intervening in pharma company mergers and acquisitions if they feel that they could create drug shortages.
In a Federal Register notice announcing a Nov. 27 public meeting on shortage prevention and mitigation, FDA's inter-agency drug...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
